Summit Therapeutics Surges as Lung Cancer Drug Shows Survival Benefit
Summit Therapeutics announced positive overall survival data for its lung cancer drug ivonescimab in a Phase 3 trial, sending shares soaring. The drug could challenge established PD-1 inhibitors, but regulatory...






